MDxHealth S.A. (MDXH) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Diagnostics & Research secteur d'activité. Le siège social de l'entreprise est situé à Herstal, Belgium. Le PDG actuel est Michael K. McGarrity.
MDXH a date d'introduction en bourse 2021-11-04, 312 employés à temps plein, cotée sur le NASDAQ Capital Marke, une capitalisation boursière de $116.6M.
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
